Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE April 24, 2017

Immune Pharmaceuticals Announces Corporate Restructuring | Read more 


PRESS RELEASE April 24, 2017

Immune Receives Nasdaq Letter | Read more 


PRESS RELEASE April 20, 2017

Immune Pharmaceuticals Signs Letter of Intent with Pint Pharma Regarding License and Commercializion of Ceplene® in Latin America | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events